CSPC Pharmaceutical Group Limited (HKEX: 01093) announced that SYS6043, a humanized monoclonal antibody-drug conjugate (ADC) targeting B7-H3, has been granted Breakthrough Therapy Designation by China’s National Medical Products Administration (NMPA) for the treatment of platinum-resistant ovarian cancer, primary peritoneal carcinoma, and fallopian tube cancer as monotherapy. The designation represents the first major regulatory milestone for SYS6043, which has no prior approvals in any jurisdiction.
China’s NMPA Breakthrough Therapy Designation is functionally analogous to the US FDA designation, designed to accelerate clinical development and regulatory review for drugs targeting serious conditions with preliminary evidence of substantial clinical improvement over available therapies.
The clinical data package supporting the designation, as described by CSPC, showed that SYS6043 demonstrated more durable anti-tumor activity than both non-platinum mono-chemotherapy and mirvetuximab soravtansine (Elahere, AbbVie), reportedly doubling progression-free survival (PFS) while maintaining a manageable safety profile. The announcement did not disclose specific response rates, patient numbers, or data cutoff dates. SYS6043 has now formally entered a Phase III confirmatory trial in the platinum-resistant ovarian cancer indication.
SYS6043 targets B7-H3 (CD276), a cell surface immune checkpoint ligand broadly overexpressed across multiple solid tumor types. The antibody component binds selectively to B7-H3 on tumor cells, delivering a cytotoxic payload directly to the target. CSPC is also evaluating SYS6043 in first- and second-line small cell lung cancer and breast cancer, consistent with a broader multi-tumor ADC strategy.